Combinations, Sequencing Will Optimize HR+ Breast Cancer Treatment, Expert Says
William J. Gradishar, MD, summarizes the need for new strategies to alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
Immunotherapies, Targeted Agents, and More on Horizon in Treatment of TNBC
Hope S. Rugo, MD, discusses immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.
Androgen Receptor Antagonists Approach Primetime for Breast Cancer
Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.
More Strategies Needed to Overcome Resistance, Progression in HR-Positive Breast Cancer
William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.
Researchers Exploring Potential Therapeutic Vaccine for Advanced HCC
Researchers are further exploring the possibility of using an immunotherapeutic vaccinia virus to treat advanced hepatocellular carcinoma (HCC), according to Ghassan K. Abou-Alfa, MD.
Study Shows Promising Results in Using Midostaurin to Treat Advanced Mastocytosis
According to phase II findings published in <em>The New England Journal of Medicine</em><sup>1</sup>, <sup> </sup>multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate (ORR) of 60% in patients with advanced systemic mastocytosis.
NCCN Issues Updated Recommendation for Optune as a Treatment for GBM
The National Comprehensive Cancer Network has issued an updated recommendation for Optune for use in combination with temozolomide as standard treatment for patients with newly diagnosed glibolastoma multiforme.
After Decades of Research, Potential for TILs in Melanoma Is Higher Than Ever
Tumor infiltrating lymphocyte (TIL) technology represents an intriguing way of overcoming the immunosuppressive power of cancer, according to Jeffrey S. Weber, MD, PhD.
Pilot Study for EGFRvIII-positive Glioblastoma Treatment Shows Promise
A chimeric antigen receptor T-cell therapy used in patients with EGFRvIII-positive glioblastoma multiforme during a pilot study showed promising results, according to two leading researchers in the field presenting at the 2015 Society of Neuro-Oncology Annual Meeting.
Dr. Carl June Discusses Management of Neurotoxicity From CAR T-Cell Therapy
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
Addition of Olaratumab to Doxorubicin Extends Survival by Nearly One Year in Soft Tissue Sarcoma
The addition of olaratumab to doxorubicin improved overall survival (OS) by nearly 1 year in patients with advanced soft tissue sarcoma, according to final results of a phase Ib/II study.
Diagnosis, Treatment of HCC Remains Challenging
Laura Dawson, MD, provides insight into the diagnosis and treatment of hepatocellular carcinoma.
Adding Chemo to ADT Shows Survival Advantage in Second Large Prostate Cancer Study
Adding docetaxel to standard androgen deprivation therapy significantly improved overall survival in men with newly diagnosed, hormone-naÃ¯ve advanced prostate cancer.
CAR Therapy Exceeds 90% Complete Remission Rate in Pediatric ALL
The chimeric antigen receptor (CAR) T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Dr. Monk Discusses Vascular Disrupting Agents in Ovarian Cancer
To gain insight into this novel approach and its potential benefit, Targeted Oncology interviewed Bradley J. Monk, MD, FACOG, FACS, who presented phase II results at the 2015 SGO's Annual Meeting on Women's Cancer.
Pembrolizumab Bests Ipilimumab in Frontline Setting
Pembrolizumab (Keytruda) yielded significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase III trial of patients with advanced melanoma.
Novel Bispecific Immunotherapy Yields Responses in Melanoma
IMCgp100, an anti-CD3 antibody fragment fused to a gp100-specific T cell receptor, yielded long-lasting responses in patients with advanced melanoma.
Pembrolizumab Beats Ipilimumab in Frontline Treatment of Melanoma
A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival (PFS) and overall survival (OS) endpoints and will be stopped early.
Lapatinib Flops, Solidifying Standard Treatment of HER2-Positive MBC
First-line treatment with lapatinib (Tykerb) and a taxane failed to improve progression-free survival (PFS) versus trastuzumab (Herceptin) plus a taxane in patients with HER2-positive metastatic breast cancer, according to final results from the phase III MA.31 trial.
Q & A With Dr. Andrew Evens: Frontline Bortezomib in MCL
To gain new insight on bortezomibâ€™s use in the frontline MCL setting, Targeted Oncology interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center.
SBLA Accepted for Adjuvant Ipilimumab in Melanoma
The FDA has accepted a supplemental Biologics License Application (sBLA) for ipilimumab (Yervoy) as an adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.
Sorafenib, Sunitinib Fail Post-Surgery in RCC
Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial. These results were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.
Czuczman Addresses Question of Sequencing Therapies in Follicular Lymphoma
Follicular lymphoma (FL) is a slow-growing and typically asymptomatic disease, characterized by many relapses.
Winter Hematology Meeting Highlighted by Talks on Immunotherapy, Personalized Medicine
Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.
Integrating Olaparib into Clinical Practice Represents Important Step for Oncologists, Patients
To gain insight into the integration of olaparib (Lynparza) into clinical practice, Targeted Oncology interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.
Ixazomib (MLN9708) Meets PFS Endpoint in Phase III Myeloma Trial
The proteasome inhibitor ixazomib (MLN9708) met its primary endpoint of improving PFS at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.
More Positive Data for Dabrafenib/Trametinib in Melanoma
The risk of death was significantly reduced for patients with BRAFV600E/K mutation-positive metastatic melanoma treated with dabrafenib and trametinib compared with dabrafenib alone.
Ibrutinib Approved for WaldenstrÃ¶mâ€™s Macroglobulinemia
The FDA has expanded the approval of ibrutinib (Imbruvica) for the treatment of patients with WaldenstrÃ¶mâ€™s Macroglobulinemia.
Enzalutamide Improves PFS By Nearly 10 Months Over Bicalutamide in mCRPC
Topline results from the phase II TERRAIN trial showed enzalutamide increased progression-free survival (PFS) by nearly 10 months compared with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Olaparib Approved for Advanced Ovarian Cancer
The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.
2 Clarke Drive Cranbury, NJ 08512